Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

Status Recruiting

Clinical Trial Summary

Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the disease, but there is a food additive that includes acetate . We suggest an early treatment with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any case the treatment will be stopped at the age of 22 months, when myelinization is ended.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Canavan Disease

Clinical Trial Details

NCT number	NCT00724802
Study type	Interventional
Source	Shaare Zedek Medical Center
Contact	Gheona Alterescu, MD
Phone	972-2-6666435
Email	gheona@szmc.org.il
Status	Recruiting
Phase	N/A
Start date	March 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04998396` - A Study of AAV9 Gene Therapy in Participants With Canavan Disease	Phase 1/Phase 2
Withdrawn	`NCT00657748` - Lithium and Acetate for Canavan Disease	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Recruiting	`NCT04126005` - Natural History Study of Patients With Canavan Disease
Completed	`NCT02851563` - A Natural History Study of Canavan Disease
Completed	`NCT01999257` - Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.	N/A
Active, not recruiting	`NCT02699190` - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting	`NCT03047369` - The Myelin Disorders Biorepository Project
Recruiting	`NCT04833907` - rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease	Phase 1/Phase 2
No longer available	`NCT05317780` - Canavan-Single Patient IND